SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin inches up as its arm gets nod to market generic version of Spiriva

29 May 2023 Evaluate

Lupin is currently trading at Rs. 782.95, up by 3.30 points or 0.42% from its previous closing of Rs. 779.65 on the BSE.

The scrip opened at Rs. 780.15 and has touched a high and low of Rs. 788.20 and Rs. 780.00 respectively. 

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 799.65 on 15-May-2023 and a 52 week low of Rs. 592.55 on 17-Jun-2022.

Last one week high and low of the scrip stood at Rs. 788.20 and Rs. 766.05 respectively. The current market cap of the company is Rs. 35478.95 crore.

The promoters holding in the company stood at 47.08%, while Institutions and Non-Institutions held 42.52% and 10.40% respectively.

Lupin’s Canada subsidiary -- Lupin Pharma Canada, has received approval from Health Canada to market a generic version of Spiriva (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD), in Canada.

Tiotropium Bromide Inhalation Powder is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also used to relieve wheezing, shortness of breath, coughing, and chest tightness in patients with COPD. Tiotropium Bromide Inhalation Powder (RLD Spiriva) had estimated annual sales of $42 million in Canada.  

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.


Lupin Share Price

2249.70 -128.20 (-5.39%)
11-May-2026 15:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1282.15
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2249.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×